Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320559 | 0.76 | CA2 (0.47) | CA2PARP1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL4973068 | 0.76 | CA2 (0.47) | CA2PARP1HTTMTNR1ACYP1B1 | |
| SCHEMBL3763119 | 0.74 | CA2 (0.45) | CA2PARP1HTTMTNR1APOLB | |
| SCHEMBL4621703 | 0.74 | CA2 (0.45) | CA2PARP1HTTMTNR1ACYP1B1 | |
| SCHEMBL3639081 | 0.74 | CA2 (0.45) | CA2PARP1HTTMTNR1ACYP1B1 | |
| SCHEMBL4333283 | 0.74 | CA2 (0.45) | CA2PARP1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL9423459 | 0.74 | CA2 (0.45) | CA2PARP1HTTMTNR1ACYP1B1 | |
| SCHEMBL437597 | 0.74 | CA2 (0.50) | CA2PARP1ALOX5ITGB2ICAM1 | |
| SCHEMBL11575701 | 0.73 | MAPT (0.36) | CA2HTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL17644228 | 0.73 | CA2 (0.40) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887346-A1 | AN EFFICIENT AND ENVIRONMENT FRIENDLY PROCESS FOR CHLOROMETHYLATION OF SUBSTITUTED BENZENES | Anthea Aromatics Private Limited (IN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020250018-A1 | AN EFFICIENT AND ENVIRONMENT FRIENDLY PROCESS FOR CHLOROMETHYLATION OF SUBSTITUTED BENZENES | ANTHEA AROMATICS PRIVATE LIMITED (IN) | 2020-12-17 | — | — | WO | disclosed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2144903-A1 | SUBSTITUTED DEUTERIUM ENRICHED THIOPHENES FOR THE TREATMENT OF HYPERTENSION | Auspex Pharmaceuticals Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008124803-A1 | SUBSTITUTED DEUTERIUM ENRICHED THIOPHENES FOR THE TREATMENT OF HYPERTENSION | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7402709-B2 | Process for synthesizing heliotropine and its derivatives | ENDURA S.P.A. (IT) | 2008-07-22 | — | — | US | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070100167-A1 | Process for synthesizing heliotropine and its derivatives | ENDURA S.P.A. (IT) | 2007-05-03 | — | — | US | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
| US-4427666-A | 3,5-Dihalogeno-1,2-methylenedioxybenzene arthropodicide synergizing agents | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-24 | — | — | US | disclosed |
| EP-0004902-B1 | BENZODIOXOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNERGISTS IN PESTICIDES | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
| EP-0004902-A2 | Benzodioxole derivatives, process for their preparation and their use as synergists in pesticides | BAYER AG (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | CA2 1910/4885PARP1 2592/4885HTT 2521/4885 |
| US-20070100167-A1 | Process for synthesizing heliotropine and its derivatives | ADH1C, ADH1A, HAO2 | CA2 156/4885PARP1 1375/4885HTT 3192/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | CA2 1637/4885PARP1 3871/4885HTT 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.